Mon, 06 Apr 2026
Axplora Expands Farmabios Site with New R&D Hub to Boost High-Potency API Manufacturing
Axplora, a global leader in complex active pharmaceutical ingredient (API) manufacturing, announced a major milestone in its $60 million investment programme at its Farmabios site in Gropello Cairoli. The latest phase includes construction of a new 4,500 m², three-storey R&D and laboratory hub, designed to accelerate development, expand execution capacity and deliver cost-efficient high-potency manufacturing at scale.
Martin Meeson, Chief Executive Officer of Axplora, said: “This investment is about enabling our customers to move more quickly at scale to and through the clinic, helping them bring their products to patients sooner. As pharma pipelines consist of molecules of higher potency and additional complexity, customers are looking to avoid delays through fragmented supply chains. By expanding R&D, analytical and quality capabilities alongside large-scale HPAPI production, we are shortening development cycles and helping them control cost while accelerating time to market.”
He added: “Axplora already manufactures 6 of the 14 FDA-approved commercial ADCs, and we continue to see strong momentum across ADC and other high-potency programmes. This expansion ensures we remain ahead of demand and fully aligned with the needs of innovators bringing next-generation therapies to patients.”
Mario Di Giacomo, Managing Director of Farmabios, commented: “Our customers are increasingly looking to move quickly without compromising quality. This new R&D hub strengthens our ability to deliver integrated, end-to-end programmes within a single site. By reducing complexity and avoiding unnecessary transfers, we improve both timeline predictability and overall programme costs.”
Featured Recruiters
